enGene Holdings Inc. (ENGN)
| Previous close | 8.79 |
| Open | 9.74 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 9.74 - 10.88 |
| 52-week range | 6.69 - 47.17 |
| Volume | |
| Avg. volume | 56,646 |
| Market cap | 447.404M |
| Beta (5Y monthly) | -0.39 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
enGene to Present at the Jefferies Global Healthcare Conference
BOSTON & MONTREAL, May 29, 2024--enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced that Jason Hanson, Chief Executive Officer, will present a corporate overview at the Jefferies Global Healthcare Conference in New York City, on June 5, 2024, at 12:30 p.m. ET.
- Business Wire
enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors
BOSTON & MONTREAL, May 15, 2024--enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company’s 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a
- PR Newswire
enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting
enGene Holdings Inc. (Nasdaq: ENGN) or ("enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced an oral presentation at the American Urology Association (AUA) 2024 Annual Meeting being held May 3-6, 2024 in San Antonio, Texas.
